Jiangsu Hengrui Medicine has been granted a patent for a LAG-3 antibody and its pharmaceutical applications, including inhibiting tumor cell growth. The method involves administering the antibody or its fragment with specific complementarity determining regions to a subject. GlobalData’s report on Jiangsu Hengrui Medicine gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jiangsu Hengrui Medicine, Cancer treatment biomarkers was a key innovation area identified from patents. Jiangsu Hengrui Medicine's grant share as of May 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-lag-3 antibody for inhibiting tumor cell growth
A recently granted patent (Publication Number: US11981733B2) outlines a method for inhibiting the growth of tumor cells in a subject by administering an anti-LAG-3 antibody or its antigen-binding fragment. The antibody includes specific complementarity determining regions in its heavy and light chain variable regions, targeting diseases associated with LAG-3, such as various types of cancer including ovarian, melanoma, prostate, breast, and lung cancer, among others. The patent specifies the sequences of the complementarity determining regions and the use of murine, chimeric, or humanized antibodies for treatment.
Furthermore, the patent details the specific sequences and regions of the anti-LAG-3 antibody, including the heavy and light chain variable regions, constant regions, and potential mutations for enhanced efficacy in treating cancer. The method described in the patent focuses on utilizing humanized antibodies with specific sequences to target LAG-3, providing a novel approach to cancer treatment in human subjects. The patent emphasizes the importance of the antibody's structure and composition in effectively inhibiting tumor cell growth, highlighting the potential for personalized and targeted therapies in the field of oncology.
To know more about GlobalData’s detailed insights on Jiangsu Hengrui Medicine, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
